• EdU Imaging Kits (Cy3): S-Phase Guide

  2026-09-18

  Learn how EdU Imaging Kits (Cy3), SKU K1075, support reproducible S-phase DNA synthesis measurement in microscopy and flow cytometry. This scenario-based guide covers assay design, CuAAC workflow choices, interpretation limits, and practical vendor selection.

• Phosbind Biotin for Context-Free Phosphoprotein Blots

  2026-09-18

  Phosbind Biotin enables sequence-independent protein phosphorylation analysis through dinuclear metal complex phosphate binding. This article connects the reagent to the PtrbZIP12 drought-response study and explains how to interpret phosphate-binding Western Blots alongside functional evidence.

• GlycoRNA–RBP Domains and TAT Peptide Entry

  2026-09-17

  The reference preprint presents evidence that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanoclusters rather than existing as isolated surface components. These RNA-dependent domains provide interaction sites for the cell-penetrating peptide TAT, linking cell-surface molecular organization to peptide internalization and offering a framework for studying noncanonical surface proteomes.

• Doxorubicin Workflows for Senescence Assays

  2026-09-17

  Use Doxorubicin, also known as Adriamycin, as a controlled DNA-damage benchmark for apoptosis, senescence, and combination studies. This workflow pairs a practical anthracycline exposure design with the reference study’s Lactobacillus plantarum DS0037 nanovesicle model to distinguish broad cytotoxicity from senescent-cell-selective effects.

• Cucurbitacin I: A Systems Assay Strategy

  2026-09-16

  Cucurbitacin I and JSI-124 enable mechanism-resolved studies of STAT3 signaling, apoptosis, invasion, and tumor response. This article adds a systems-level assay perspective inspired by human SAN–cardiac plexus assembloids, while clearly separating evidence from cross-domain experimentation.

• Ultrasonic Implantable TTF: Mechanism and Findings

  2026-09-16

  The reference study presents a battery-free implantable Tumor Treating Field system powered by focused ultrasound and built around shape-engineered BaTiO3 pyramid receivers. Its improved acoustic-to-electric conversion, angular tolerance, and localized field delivery enabled glioblastoma growth suppression in vitro and reduced Ki-67 staining in a short pilot animal study.

• PSPro Enables All-at-Once Spatial Proteomics

  2026-09-15

  Mao and colleagues introduce PSPro, a proximity-labeling workflow that captures cell-type-associated proteomes directly from complex tissue slices. By combining antibody-guided biotinylation, affinity purification, and optional laser microdissection, the method profiles thousands of proteins while retaining cellular and spatial context.

• Roscovitine: Reliable Cell Assay Design

  2026-09-15

  This scenario-driven guide shows how Roscovitine (Seliciclib, CYC202), SKU A1723, can improve the interpretation and reproducibility of cell-cycle, viability, proliferation, and cytotoxicity experiments. It connects documented CDK potency and formulation data with practical controls, assay design, and responsible translational interpretation.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-09-14

  The 2024 Theranostics study identifies low PPP2R2A, encoding the PP2A B55α regulatory subunit, as a potential biomarker of CHK1 inhibitor sensitivity in high-grade serous ovarian cancer. Its experiments connect PPP2R2A deficiency with excessive replication initiation, c-Myc-associated replication stress, and dependence on CHK1, including in models resistant to PARP inhibition.

• Stattic Workflows for STAT3-Driven Cancer Research

  2026-09-14

  Build a practical Stattic workflow for STAT3 pathway validation, apoptosis induction in cancer cells, and radiation-response studies. This guide connects concentration planning, orthogonal readouts, assay controls, and troubleshooting for head and neck squamous cell carcinoma (HNSCC) research.

• EZ Cap™ OVA mRNA: From Transcript to Assay

  2026-09-13

  EZ Cap™ OVA mRNA provides a standardized Ovalbumin mRNA input for immune response modeling, gene expression studies, and vaccine development research. This guide connects transcript design with delivery controls so researchers can distinguish antigen biology from carrier-driven inflammation.

• Indometacin Sodium: Designing Better Assays

  2026-09-12

  Indometacin Sodium is a versatile COX inhibitor for inflammation research, with additional relevance to Wnt/β-catenin and cell-state assays. This guide presents a decision-centered framework for selecting concentrations, endpoints, controls, and translational boundaries.

• Berberine Hydrochloride in Gut–Bone Research

  2026-09-11

  A practical research guide to using Berberine hydrochloride in gut–bone axis, metabolic, antibacterial, and osteoimmune workflows. It translates recent tuft-cell findings into assay choices, dosing controls, and troubleshooting steps while keeping preclinical conclusions separate from clinical claims.

• p-Tau Ser356, NUAK1, and Alzheimer’s Disease Pathology

  2026-09-11

  Taylor et al. characterize p-tau Ser356 as a pathology-associated tau species that rises with Alzheimer’s disease progression and is frequently present in neurofibrillary tangles. Their cross-species brain-slice experiments show that NUAK inhibition produces distinct responses in mouse and human tissue, an important consideration for evaluating tau-directed interventions.

• BAY-826: A Mechanistic Probe for Retinal Signaling

  2026-09-10

  BAY-826 is a potent small molecule inhibitor suited to carefully controlled studies of angiogenesis-linked and retinal neuron-survival pathways. This article focuses on causal assay design, Müller cell–neuron crosstalk, and the evidence needed to interpret BAY-826 experiments without overstating pathway conclusions.

7998 records 1/534 page Next 12345 下5页 Last page